sciclone pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals

SCLN 11.15

0.0%

Oct 20 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Skywatcher who wrote (1106)	6/29/2003 2:46:43 AM
From: JEB	Read Replies (2) of 1137

Ignore my last post. I've been researching HCV lately, ...and, ...well, ...screwed than one up. I was referring to HCV therapies. Allow me to set the record straight here. For HBV therapy: Pegintron (Schering Plough) Interferon therapy has the side effects I mentioned earlier. Epivir HBV (GlaxoSmithKline) Lamivudine therapy has little side effects but can cause mutant HBV cells. Hepsera (Gilead) Adefovir Dipivoxil therapy is the newest on the market and has little side effects except for kidney problems which appear to be reversible. Zadaxin would be the first adjuvant (secondary drug - cocktail therapy) approved for HBV therapy in Japan. Also, any drug like Zadaxin that can take the "edge" off the chemotherapy drugs has got to help take the "edge" off of these drugs as well.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next